Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 296-297 , July 2010

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: Three areas for future research: Which areas to target? Which particle size to deliver? Which device to use?

  • Bart L. Rottier

      Affiliations

    • Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, The Netherlands
    • ,
  • Anne H. de Boer

      Affiliations

    • Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, The Netherlands
    • ,
  • Eric J. Duiverman

      Affiliations

    • Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, The Netherlands

Received 7 December 2009 ,Revised 23 March 2010 ,Accepted 24 March 2010.

References 

  1. Heijerman H, Westerman E, Conway S, Touw D, Döring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cystic Fibrosis. 2009;8:295–315
  2. Linnane BM, Hall GL, Nolan G, Brennan S, Stick SM, Sly PD, et al. AREST-CF.Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med. 2008 Dec 15;178(12):1238–1244
  3. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, et al. Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF): lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009 Jul 15;180(2):146–152
  4. Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009 Jun;44(6):547–558
  5. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93–99Jan
  6. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986 Apr;5(4):319–324
  7. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β-agonist particle size. Am J Respir Crti Care Med. 2005;172:1497–1504
  8. Morrow PE, Yu CP. Models of aerosol behaviour in airways. In:  Moren F,  Newhouse MT, Dolovich  editor. Aerosols in Medicine. Principles, Diagnosis and Therapy. Elsevier Science Publishers (Biomedical Division); 1985;p. 149–191
  9. Rottier BL, van Erp CJP, Sluyter TS, Heijerman HGM, Frijlink HW, de Boer AH. Changes in the performance of the Pari eFlow® Rapid and Pari LC Plus™ during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv. 2009;22(3):263;Sep
  10. Denyer J, Dyche A, Nikander K. Breathing patterns in adult patients. J Aerosol Med. 1997;10:99

PII: S1569-1993(10)00036-6

doi: 10.1016/j.jcf.2010.03.009

Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 296-297 , July 2010

Article Tools